Development asset linked to Autolus in public FDA and regional records.
pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Autolus drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
Autolus pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Autolus drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Autolus in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Autolus in public FDA and regional records.
-
Development asset linked to Autolus in public FDA and regional records.
-
Development asset linked to Autolus in public FDA and regional records.
-
obecabtagene autoleucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Autolus's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
US regulatory status: approved.
-
Development asset linked to Autolus in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
Development asset linked to Autolus in public FDA and regional records.
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to Autolus in public FDA and regional records.
-
Development asset linked to Autolus in public FDA and regional records.
-
Development asset linked to Autolus in public FDA and regional records.
-
Development asset linked to Autolus in public FDA and regional records.